Efficacy and safety of pomalidomide as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma patients refractory to a lenalidomide-containing combination regimen.

Berenson, James R.; Cohen, Alexa; Spektor, Tanya M.; Lashkari, Ashkan; Mackintosh, Roy; Bessudo, Alberto; Robinson, Michael Oren; Jhangiani, Haresh S.; Gabrail, Nashat; Nakhoul, Ibrahim; Kubba, Samir; Neidhart, Jeffrey D.; Maluso, Tina; Swift, Regina A.; Vescio, Robert

doi:10.1200/jco.2018.36.15_suppl.e20012

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pomalidomide is a third-generation immunomodulating agent with similar structural and mechanistic properties to those of lenalidomide, but with shown efficacy in the treatment of lenalidomide-refractory myeloma. 3,4 In phase 2 and phase 3 trials, overall response rate and median progression-free survival of approximately 30% and 4 months, respectively, have been reported in patients who were previously treated with lenalidomide and bortezomib. 5,6 The addition of daratumumab and elotuzumab with pomalidomide and dexamethasone has been shown to improve response rates to 53% and 60%, respectively.…”

Section: Introductionmentioning

confidence: 99%

Pomalidomide desensitization for hypersensitivity: A case report

Park

Huang

Monteleone

et al. 2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Pomalidomide is an immunomodulating agent that is used to treat relapsed and/or refractory multiple myeloma. Although the incidence of hypersensitivity with pomalidomide is not well documented, the most common type of hypersensitivity involves a cutaneous reaction. Previous reports have successfully utilized a desensitization protocol in patients who developed hypersensitivity to pomalidomide. Here we describe a case of a patient who developed urticaria on pomalidomide and successfully underwent a desensitization using the previously reported method in a case report. Case report A 68-year-old woman with relapsed multiple myeloma and no known drug allergies developed urticaria a day after taking the first dose of pomalidomide. Management and Outcome The patient underwent a 10-step desensitization process in the medical intensive care unit without any reported adverse events. The following day in the medical intensive care unit, the patient was able to tolerate a full dose of pomalidomide with no further reactions and was discharged with instructions to take a full dose of pomalidomide daily for 21 days out of a 28-day cycle. The patient was followed up in the outpatient clinic and noted no further reactions from pomalidomide at the three-month visit. Discussion The 10-step desensitization protocol with pomalidomide was well tolerated in the patient with hypersensitivity to pomalidomide. Whether this approach would work in patients with more severe reactions such as anaphylaxis and angioedema is still unknown.

show abstract